The Medicines Company has filed lawsuits against Teva Parenteral Medicines (Teva), Pliva Hrvatska and related entities in the US District Court for the District of Delaware alleging patent infringement based on Abbreviated New Drug Applications (NDA) seeking FDA approval to market and sell generic versions of The Medicines Company’s Angiomax product prior to expiration of US Patent No 7598343 (the ‘343 patent).
Angiomax (bivalirudin) is an anticoagulant currently approved in the US and other countries for use in patients undergoing coronary angioplasty procedures. Angiomax works by directly inhibiting thrombin, to help prevent clot formation during angioplasty.
Reportedly, each lawsuit alleges infringement of the ‘343 patent which was issued on October 6, 2009. As previously announced, The Medicines Company has patent infringement lawsuits pending against the same parties in the US District Court for the District of Delaware for infringement of its US Patent No 7502727.